Schlagwort(e):
Androgens.
;
Electronic books.
Materialart:
Online-Ressource
Seiten:
1 online resource (252 pages)
Ausgabe:
1st ed.
ISBN:
9781620811887
Serie:
Endocrinology Research and Clinical Developments
URL:
https://ebookcentral.proquest.com/lib/geomar/detail.action?docID=3021186
Sprache:
Englisch
Anmerkung:
Intro -- ANDROGENS -- ANDROGENS -- Contents -- Preface -- Androgen Deprivation Therapy for Advanced Prostate Cancer on the Ground of Androgen Milieu in the Prostate -- Abstract -- Abbreviations -- Introduction -- Androgen Milieu in Blood -- Androgen Milieu in the Prostate -- Prostate Cancer Aggressiveness and the Androgen Milieu in the Prostate and in Blood -- Intraprostatic Androgen Milieu during Androgen Deprivation Therapy -- Androgen Milieu in the Castration-Resistant Prostate Cancer -- Clinical-Translational Advances of Prostate Cancer -- Gonadotrophin-Releasing Hormone (GnRH) Antagonists: Degarelix -- Cytochrome P450, Family 17, Subfamily A, Polypeptide 1 (CYP17A1) Inhibitors -- Abiraterone Acetate (Zytiga, Johnson & -- Johnson) -- Orteronel (TAK-700) [(1S)-1-(6,7-Dimethoxy-2-Naphthyl)-1-(1H-Imidazol-4-Yl)-2-Methylpropan-1-Ol] -- TOK-001 (VN/124-1) [3 -Hydroxy-17-(1H-Benzimidazole-1-Yl)Androsta-5,16-Diene] -- 3.-Hydroxysteroid Dehydrogenase Inhibitors -- Apoptone (HE3235) (17 -Ethynyl-5 -Androstan-3 , 17 -Diol) -- Inhibitors Targeting Androgen Receptor -- A New Androgen Receptor Antagonist, MDV3100 -- A New Androgen Receptor Antagonist, ARN-509 -- An Inhibitor of the Amino Terminal Domain (NTD) of the AR: EPI-001 -- The Prospects of the Androgen Deprivation Therapy on the Ground of Androgen Milieu in the Prostate -- Conclusion -- References -- Clinical Model of Androgen Deficiency - Clinical Model of Androgen Deficiency - Clinical Model of Androgen Deficiency - Androgen Deprivation Therapy and Its Effect on Bone Metabolism, Metabolism and Cognitive Functions -- Introduction -- Methods -- Androgen Deprivation Therapy (ADT) -- Testosterone: A Basal Overview of Biosynthesis, Metabolism and Its Action -- Androgens and Bone Metabolism -- ADT and Its Side Effects -- Bone Loss and Osteoporosis -- Osteoporosis.
,
Diagnosis of Osteoporosis -- ADT, PCa and Clinical Aspects of Bone Disease -- Treatment of ADT Induced Osteoporosis -- Androgens and Cognitive Functions -- Potential Mechanisms of Action -- Cognitive Functions and ADT -- Androgen Deprivation Therapy and Changes in Body Composition -- ADT and Insulin Resistance -- Early Metabolic Changes -- Late Metabolic Changes -- ADT and Lipid Alterations -- ADT, Metabolic Syndrome and Cardiovascular Disease -- References -- The Role of Testosterone in Male Erectile Dysfunction -- 1. Erectile Dysfunction -- 2. Definitions -- 2.1. Total Testosterone -- 2.2. Free Testosterone -- 2.3. Bio-Available/Bioactive Testosterone -- 3. Hypogonadism -- 3.1. Late Onset Hypogonadism -- 3.2. Hypogonadism Prevalence -- 4. Relationship between Testosterone and ED -- 5. Physiology of Erection -- 6. Influence of Testosterone on Penile Erection -- 6.1. NOS/cGMP Pathway -- 6.2. Source of NO -- 6.3. Phosphodiesterases (PDE) -- 7. Making the Diagnosis of Hypogonadism and Working up Erectile Dysfunction -- Patient History -- Physical Exam -- Laboratory Studies -- Specific Diagnostic Tests -- 7.1. Questionnaires -- 7.2. Laboratory Diagnosis -- 7.3. Total Testosterone -- What is the Lower Level of Testosterone Required to Maintain Erection? -- 7.4. Free Testosterone -- 7.5. Calculated Free Testosterone -- 7.6. Other Endocrine Markers -- 8. Testosterone and Testosterone Replacement Therapy (TRT) -- 8.1. Safety, Tolerability and Specific Considerations -- 8.2. Testosterone and PDE5 Inhibitors (PDE5-I) in ED -- References -- Roles of Androgen Receptor in Normal Prostate Development and Prostate Cancer Progression -- 1. Introduction -- 2. Dual Roles of the AR in Normal Prostate Development -- 2.1. Stromal AR: Proliferation Stimulator and Survival Factor -- 2.2. Epithelial AR: Survival Factor for Epithelial Luminal Cells.
,
2.3. Epithelial AR: Suppressor for Epithelial Basal Intermediate Cell Proliferation -- 2.4. Epithelial AR: Survival Factor for Stromal Smooth Muscle Cell Differentiation -- 3. AR Dual Roles in Prostate Cancer Progression and Metastasis -- 3.1. Stromal AR: Stimulator for Tumor Progression and Metastasis -- 3.2. Epithelial AR: Survival Factor for Tumor Progression and Metastasis in Luminal Cells -- 3.3. Epithelial AR: Suppressor for Tumor Progression and Metastasis in Basal Intermediate Cells -- 3.4. Epithelial AR: Suppressor of Prostate Cancer Metastasis -- 4. AR Dual Roles in Human Prostate Cancer Cell Lines -- 4.1. AR in PC3 Cells: Suppressor for Proliferation and Metastasis -- 4.2. AR in LNCaP Cells: Proliferation Stimulator and Suppressor -- 4.3. AR in CWR22Rv1 Cells: Proliferation Stimulator and Suppressor -- 4.4. AR in PC346C Prostate Cancer Cells: Proliferation Stimulator and Suppressor -- 5. AR Dual Roles in Prostate Cancer Stem Cell Progression -- 6. AR Dual Roles and Human Prostate Cancer Clinical Data -- 7. The Impact of AR Dual Roles on Current Clinical ADT -- 7.1. Challenge to Current ADT -- 7.2. Target the AR at an Early Stage -- 7.3. Concomitant Treatment of AR Antagonism with Anti-Metastasis Agents -- Future Direction -- Conclusion -- References -- Endogenous Pathways for Steroidogenesis and Androgen Signalling in Prostate Cancer Cells -- Summary -- Introduction -- The Prostate -- Androgen Receptor -- Prostate Cancer and Treatment -- Links between Androgen Levels and Prostate Cancer Risk -- Steroidogenesis and Prostate Cancer -- Conclusion -- References -- The Role and Effects of Novel Androgen Therapy in the Treatment of Prostate Cancer -- Abstract -- I. Introduction -- II. Emergence of Castration Resistance: Androgen Regulation and Signaling -- III. Clinical Studies.
,
IV. Adverse Effects of Targeting Androgen Regulation: Recent Findings -- Conclusion -- References -- Androgens and Male Fertility: Spermatogenesis and Contraception -- Abstract -- Introduction -- Androgens -- Role of Androgens in Male Sexual Development -- Spermatogenesis -- Hypthalamic-Pituitary-Gonadal Axis -- Role of the Androgen Receptor -- Classical Testosterone Signaling Pathways -- Non-Classical Testosterone Pathways in Sertoli Cells -- Male Hormone Contraception -- References -- Androgens, Cognition and Social Behavior in Children* -- Introduction -- Androgens -- Testosterone -- Androstenedione -- Dehydroepiandrosterone (DHEA) -- Androgen-Secreting Glands -- Suprarenal Glands -- Gonads -- Testicles -- Ovaries -- Biosynthesis of Steroid Hormones -- Action Mechanisms of Androgens -- Sexual Differentiation of the Brain and Behavior -- Sexual Differentiation -- Genetic Sex -- Gonadal Sex -- Hormonal Sex -- Effects of Organization and Activation -- Relation of Androgens to Psychological Processes -- Relationship between Androgens and Social Behavior -- Conclusion -- References -- Androgens, Androgen Suppression, and Prostate Cancer: Recent Preclinical and Clinical Findings and Implications* -- Abstract -- Introduction -- Prevention Studies -- 5-Alpha Reductase Inhibitors -- Treatment Studies -- Role of ADT in Early Prostate Cancer -- ADT Combined with Radiation -- ADT Combined with Surgery -- ADT for Patients Ineligible for Local Definitive Therapy -- Role of Continuous ADT in Biochemical Recurrence of Prostate Cancer -- Early versus Late Therapy -- Peripheral Androgen Blockade -- Role of Continuous ADT in Advanced Disease -- Combined Androgen Blockade -- Antiandrogen Monotherapy -- Antiandrogen Withdrawal -- Intermittent ADT -- Role of Intermittent ADT in Biochemically Recurrent Prostate Cancer.
,
Role of Intermittent ADT in Locally Advanced or Metastatic Prostate Cancer -- Individual Dosing Based on Testosterone Levels -- Rapid Hormonal Testosterone Cycling -- Other Agents -- Ketoconazole -- Aminoglutethimide -- Abiraterone Acetate -- ADT Combined with Other Modalities -- ADT and Chemotherapy -- ADT and Vaccines -- Adverse Effects of ADT -- Skeletal Changes and Loss of Bone Mineral Density -- Hot Flashes -- Metabolic Syndrome -- Sexual Dysfunction -- Emotional and Cognitive Side Effects -- Systemic Effects -- Biology of Castrate-Resistant Prostate Cancer -- Potentially Therapeutic Approaches Targeting AR -- Conclusion -- References -- Index.
Permalink